Rosato F, Pasupuleti R, Tomisch J, Meléndez AV, Kolanovic D, Makshakova ON, Wiltschi B, Römer W.
J Transl Med. 2022; doi: 10.1186/s12967-022-03794-w.
We developed a so-called "lectibody", a bispecific construct composed of a lectin linked to an antibody fragment. This lectibody activated cytotoxic T cells resulting in nearly complete lysis of Gb3-positive tumor cells in vitro.
